Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient-Derived iPSC Model

Clinical and Translational Science

Volumn 9, Issue 3, 2016, Pages 158-167

  Wyles, S P ^a   Hrstka, S C ^a   Reyes, S ^a   Terzic, A ^a,b   Olson, T M ^a,b   Nelson, T J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; CARVEDILOL; METOPROLOL; VERAPAMIL;

ADRENERGIC STIMULATION; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARDIAC MUSCLE CELL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RESPONSE; CELL POPULATION; CELLULAR STRESS RESPONSE; CONCENTRATION RESPONSE; CYTOPLASM; DISEASE COURSE; DNA FRAGMENTATION; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL; PHENOTYPE; PRIORITY JOURNAL;

EID: 84975060963     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12393     Document Type: Article

References (49)

1. Maron, B.J. et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 14, 1807–1816 (2006).
2. Tsirka, A.E. et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J. Am. Coll. Cardiol. 44, 391–397 (2004).
3. Hershberger, R.E., Morales, A. & Siegfried, J.D. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet. Med. 12, 655–667 (2010).
4. Towbin, J.A. et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296, 1867–1876 (2006).
5. Hershberger, R.E., Hedges, D.J. & Morales, A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 10, 531–547 (2013).
6. Fatkin, D., Otway, R. & Richmond, Z. Genetics of dilated cardiomyopathy. Heart Fail. Clin. 6, 129–140 (2010).
7. Hershberger, R.E. & Morales, A. Dilated cardiomyopathy overview. GeneReviews (Internet) 1993–2016.
8. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
9. Sun, N. et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra147 (2012).
10. Wyles, S.P. et al. Modeling structural and functional deficiencies of RBM20 familial dilated cardiomyopathy using human induced pluripotent stem cells. Hum. Mol. Genet. 25, 254–265 (2016).
11. Burkett, E.L. & Hershberger, R.E. Clinical and genetic issues in familial dilated cardiomyopathy. J. Am. Coll. Cardiol. 45, 969–981 (2005).
12. Knöll, R. et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111, 943–955 (2002).
13. Brauch, K.M. et al. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J. Am. Coll. Cardiol. 54, 930–941 (2009).
14. Li, S., Guo, W., Dewey, C.N. & Greaser, M.L. Rbm20 regulates titin alternative splicing as a splicing repressor. Nucleic Acids Res. 41, 2659–2672 (2013).
15. Wells, Q.S. et al. Whole exome sequencing identifies a causal RBM20 mutation in a large pedigree with familial dilated cardiomyopathy. Circ. Cardiovasc. Genet. 6, 317–326 (2013).
16. Guo, W. et al. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat. Med. 18, 766–773 (2012).
17. Harvey, P.A. & Leinwand, L.A. The cell biology of disease: cellular mechanisms of cardiomyopathy. J. Cell Biol. 194, 355–365 (2011).
18. Harding, S.E. et al. Acceleration of contraction by beta-adrenoceptor stimulation is greater in ventricular myocytes from failing than non-failing human hearts. Basic Res. Cardiol. 91(Suppl 2), 53–56 (1996).
19. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. & Dagenais, G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145–153 (2000).
20. Dahlöf, B. et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am. J. Hypertens. 10 (7 Pt 1), 705–713 (1997).
21. Packer, M. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 21, 1349–1355 (1996).
22. Factor, S.M., Cho, S.H., Scheuer, J., Sonnenblick, E.H. & Malhotra, A. Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. J. Am. Coll. Cardiol. 12, 1599–1604 (1988).
23. Sonnenblick, E.H., Fein, F., Capasso, J.M. & Factor, S.M. Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy. Am. J. Cardiol. 55, 179B–184B (1985).
24. Wojnicz, R. et al. Therapeutic window for calcium-channel blockers in the management of dilated cardiomyopathy: a prospective, two-centre study on non-advanced disease. Cardiology 117, 148–154 (2010).
25. Beraldi, R. et al. Rbm20-deficient cardiogenesis reveals early disruption of RNA processing and sarcomere remodeling establishing a developmental etiology for dilated cardiomyopathy. Hum. Mol. Genet. 23, 3779–3791 (2014).
26. Martinez-Fernandez, A. et al. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ. Res. 105, 648–656 (2009).
27. Hodgson, D.M. et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 287, H471–H479 (2004).
28. Liang, P. et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127, 1677–1691 (2013).
29. Communal, C., Singh, K., Pimentel, D.R. & Colucci, W.S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98, 1329–1334 (1998).
30. Refaat, M.M. et al. Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy. Heart Rhythm 9, 390–396 (2012).
31. Maatz, H. et al. RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. J. Clin. Invest. 124, 3419–3430 (2014).
32. Manning, E.P., Guinto, P.J. & Tardiff, J.C. Correlation of molecular and functional effects of mutations in cardiac troponin T linked to familial hypertrophic cardiomyopathy: an integrative in silico/in vitro approach. J. Biol. Chem. 287, 14515–14523 (2012).
33. Marston, S.B. How do mutations in contractile proteins cause the primary familial cardiomyopathies? J. Cardiovasc. Transl. Res. 4, 245–255 (2011).
34. Liu, B., Tikunova, S.B., Kline, K.P., Siddiqui, J.K. & Davis, J.P. Disease-related cardiac troponins alter thin filament Ca2+ association and dissociation rates. PLoS One 7, e38259 (2012).
35. Schober, T. et al. Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Circ. Res. 111, 170–179 (2012).
36. Xue, S.R., Xue, Y. & Xue, R. Carvedilol restore cardiac calcium release channel structure and function in heart failure. Int. J. Cardiol. 116, 231–235 (2007).
37. Kao, D.P. et al. Therapeutic molecular phenotype of β-blocker-associated reverse-remodeling in nonischemic dilated cardiomyopathy. Circ. Cardiovasc. Genet. 8, 270–283 (2015).
38. Poole-Wilson, P.A. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362, 7–13 (2003).
39. Chandar, S. et al. Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated cardiomyopathy. Circ. Res. 106, 573–582 (2010).
40. Stefenelli, T., Wikman-Coffelt, J., Wu, S.T. & Parmley, W.W. Calcium-dependent fluorescence transients during ventricular fibrillation. Am. Heart J. 120, 590–597 (1990).
41. Vohra, J. Verapamil in cardiac arrhythmias: an overview. Clin. Exp. Pharmacol. Physiol. Suppl. 6, 129–134 (1982).
42. Mehta, A. et al. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. Cardiovasc. Res. 91, 577–586 (2011).
43. Goldspink, D.F., Burniston, J.G., Ellison, G.M., Clark, W.A. & Tan, L.B. Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp. Physiol. 89, 407–416 (2004).
44. Krishnamurthy, P., Subramanian, V., Singh, M. & Singh, K. Beta1 integrins modulate beta-adrenergic receptor-stimulated cardiac myocyte apoptosis and myocardial remodeling. Hypertension 49, 865–872 (2007).
45. Hakucho, A., Liu, J., Liu, X. & Fujimiya, T. Carvedilol improves ethanol-induced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats. Hepatol. Res. 44, 560–570 (2014).
46. Xu, C. et al. β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. J. Mol. Cell. Cardiol. 75, 111–121 (2014).
47. Flora, S.J. & Mehta, A. Monoisoamyl dimercaptosuccinic acid abrogates arsenic-induced developmental toxicity in human embryonic stem cell-derived embryoid bodies: comparison with in vivo studies. Biochem. Pharmacol. 78, 1340–1349 (2009).
48. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).
49. Roden, D.M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013–1022 (2004).